SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Braun J, Sieper J (April 2007) Ankylosing Spondylitis. Lancet 369, 137990.
  • 2
    Brown SA, Rosen CJ (2003) Osteopororsis. Med Clin North Am 87, 103963.
  • 3
    Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2001) Ten year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30, 2518.
  • 4
    El Maghraoui A (2004) Osteoporosis and ankylosing spondylitis. Joint Bone Spine 71, 29185.
  • 5
    Raltson SH, Urquhart GDK, Bzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 300, 5635.
  • 6
    Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C (1992) Appendicular and vertebral bone mass in ankylosing spondylitis. Arth Rheum 35, 10627.
  • 7
    Bronson WD, Walker SE, Hillman LS, Keisler D, Hoyt T, Allen SH (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25, 92935.
  • 8
    Donnelly S, Doyle DV, Denton A, Rolfe J, McCloskey EV, Spector TD (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53, 11721.
  • 9
    Mullaji AB, Upadhyay SS, Ho EK (1994) Bone mineral density in ankylosing spondylitis. DEXA comparison of control subjects with mild and advanced cases. J Bone Joint Surg Br 76B, 6605.
  • 10
    El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C (1999) Osteoporosis, Body composition, and Bone turnover in Ankylosing Spondylitis. J Rheumatol 26, 22059.
  • 11
    El Maghraoui A, Chaouir S, Bezza A, et al . (2003) Evaluation de la densité minérale osseuse au cours de la spondylarthrite ankylosante par tomodensitométrie quantitative. Rev Mar Rhum 15, 12933.
  • 12
    Tousirrot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology (Oxford) 40, 8828.
  • 13
    Juanola X, Mateo L, Nolla JM, Roig-Vilaseca D, Campoy E, Roig-Escofet D (2000) Bone Mineral Density in women with Ankylosing Spondylitis. J Rheumatol 27, 102831.
  • 14
    Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J (2005) Bone loss is detected more frequently in patients with Ankylosing Spondylitis with syndesmophytes. J Rheumatol 32, 12908.
  • 15
    Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21, 187782.
  • 16
    Toussirot E, Wendling D (2000) Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 18, S1620.
  • 17
    Meirelles ES, Borelli A, Camargo OP (1999) Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 18, 3648.
  • 18
    Lange U, Kluge A, Strunk J, Teichmann J, Bachmann G (2005) Ankylosing spondylitis and bone mineral density – what is the ideal tool for measurement? Rheumatol Int 26, 11520.
  • 19
    Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, Biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with. Ankylosing Spondylitis J Rheumatol 31, 223641.
  • 20
    Bessant R, Harris C, Keat A (2003) Audit of the Diagnosis, assessment and treatment of Osteoporosis in patients with Ankylosing Spondylitis. J Rheumatol 30, 77982.
  • 21
    Singh A, Bronson W, Walker SE, Allen SH (1995) Relative value of femoral and lumbar bone mineral density assessments in patients with ankylosing spondylitis. South Med J 88, 93943.
  • 22
    Mitra D, Elvins DM, Collins AJ (1999) Biochemical markers of Bone metabolism in Mild Ankylosing Spoondyltis and their relationship with Bone Mineral Density and Vertebral fractures. J Rheumatol 26, 22014.
  • 23
    Gratacos J, Collado A, Fillela X, et al . (1994) Serum cytokines (IL-6, TNF-a, IL-1b and IFN-G) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33, 92731.
  • 24
    Gowen M, Mundy G (1986) Actions of recombinant interleukin 1, interleukin 2 ans interferon-g on bone resorption in vitro. J Immunol 136, 247882.
  • 25
    Bertolini D, Nedwin G, Bringman T, Smith D, Mundy G (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factor. Nature 319, 5168.
  • 26
    Speden DJ, Calin AI, Ring FJ, Bhalla AK (2002) Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 29, 51621.
  • 27
    Kim HR, Kim HY, Lee SH (2006) Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 45, 1197200.
  • 28
    Nakao A, Fukushima H, Kajiya H, Ozeki S, Okabe K (April 19 2007) RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways. Biochem Biophys Res Commun. (Epub ahead of print).
  • 29
    De Keyser F, Baeten D, Van den Bosch F, et al . (2002) Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 4, 52532.
  • 30
    El Maghraoui A, Dougados M, Freneaux E, Chaussade S, Amor B, Breban M (1999) Concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease. Rheumatology 38, 5436.
  • 31
    Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16, 334.
  • 32
    Toussirot E, Nguyen NU, Dumoulin G, Reganrd J, Wendling D (1998) Insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis. Br J Rheumatol 37, 11726.
  • 33
    Hansen CA, Shagrin JW, Duncan H (1971) Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop 74, 5964.
  • 34
    Jun JB, Joo KB, Her MY, et al . (2006) Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 33, 163741.
  • 35
    Cooper C CL, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21, 187782.
  • 36
    Reid IR, Brown JP, Burckhardt P, et al . (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346, 65361.
  • 37
    Maksymowych WP, Jhangri GS, Fitzgerald AA, et al . (2002) A 6-month randomized, controlled, double-blind, dose–response comparison of intravenous pamidronate (60 versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arth Rheum 46, 76673.
  • 38
    Maksymowych WP, Jhanri GS, LeClercq S, Skeith K, Yan A, Russell AS (1998) An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25, 7147.
  • 39
    Tapia-Serrano R, Jiminez-Balderas FJ, Murrieta S, Bravo-Gatica C, Guerra R, Mintz G (1991) Testicular function in active ankylosing spondylitis. Therapeutic response to human chorionic gonadotrophin. J Rheumatol 18, 8418.
  • 40
    Baillie SP, Davidson CE, Johnson FJ, Francis RM (1992) Pathogenesis of vertebral crush fractures in men. Age Ageing 21, 13941.
  • 41
    Finkelstein JS, Klibanski A, Neer RM, et al . (1989) Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 69, 77683.
  • 42
    Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62, 3479.